Nuvation Bio (NUVB) Short-Term Debt issuances (2024 - 2025)
Nuvation Bio (NUVB) posted quarterly Short-Term Debt issuances of $11.2 million for Q4 2025, up 100.95% year-over-year from $5.6 million in Q4 2024, and up 100.95% quarter-over-quarter from $5.6 million in Q4 2024.
Nuvation Bio (NUVB) Short-Term Debt issuances (2024 - 2025) Analysis & Trends
Nuvation Bio (NUVB) has reported Short-Term Debt issuances for 2 consecutive years, with $11.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Short-Term Debt issuances rose 100.95% year-over-year to $11.2 million; the TTM figure through Dec 2025 stood at $16.8 million (up 200.95% YoY), while the FY2025 annual figure was $60.1 million, up 376.66% from the prior year.
- Short-Term Debt issuances advanced to $11.2 million in Q4 2025 per NUVB's latest filing, from $5.6 million in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $11.2 million in Q4 2025 and bottomed at $5.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.20 Mn |
| Dec 31, 2025 | 11.20 Mn |
| Dec 31, 2024 | 5.57 Mn |
| Dec 31, 2024 | 5.57 Mn |